Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 3:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 183 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Minimal Residual Disease Clear all
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Pembrolizumab, Bevacizumab, Cyclophosphamide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced May 22, 2026, 3:48 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoma
Interventions
Mosunetuzumab, Ibrutinib, Acalabrutinib, Zanubrutinib, Pirtobrutinib
Drug
Lead sponsor
Inhye Ahn
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced May 22, 2026, 3:48 AM EDT
Terminated Early Phase 1 Interventional Results available
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia in Remission, Hematopoietic Cell Transplantation Recipient, JAK2 Gene Mutation, Loss of Chromosome 17p, Mantle Cell Lymphoma, Minimal Residual Disease, Myelodysplastic Syndrome, Non-Hodgkin Lymphoma, Plasma Cell Myeloma, RAS Family Gene Mutation, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hematologic Malignancy, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Therapy-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome, TP53 Gene Mutation
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Irradiated Allogeneic Cells
Procedure · Biological
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 25, 2023 · Synced May 22, 2026, 3:48 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Interventions
Venetoclax monotherapy, Venetoclax with anti CD20 monoclonal antibody
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
9
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced May 22, 2026, 3:48 AM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Myeloid Leukemia
Interventions
MCLA-117 bispecific antibody
Drug
Lead sponsor
Merus B.V.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced May 22, 2026, 3:48 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Medulloblastoma, Medulloblastoma, Childhood, Medulloblastoma Recurrent
Interventions
Liothyronine (L-T3), Bevacizumab, Irinotecan, Temozolomide (TMZ)
Drug
Lead sponsor
Sabine Mueller, MD, PhD
Other
Eligibility
1 Year to 25 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced May 22, 2026, 3:48 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Gemtuzumab Ozogamicin, Quality-of-Life Assessment
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced May 22, 2026, 3:48 AM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Lymphoma, Multiple Myeloma, Hematologic Neoplasms
Interventions
BPX-501, Rimiducid
Biological · Drug
Lead sponsor
Bellicum Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2033
U.S. locations
5
States / cities
Atlanta, Georgia • Westwood, Kansas • Buffalo, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced May 22, 2026, 3:48 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Multiple Myeloma, Newly Diagnosed, Multiple Myeloma (MM)
Interventions
Elranatamab, Daratumumab, Lenalidomide, autologous stem cell transplantation
Drug · Procedure
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
19 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
11
States / cities
Birmingham, Alabama • Denver, Colorado • Iowa City, Iowa + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced May 22, 2026, 3:48 AM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Colorectal Cancer, Minimal Residual Disease
Interventions
Fludarabine Phosphate, Cyclophosphamide, Cetuximab, TROP2-CAR-NK Cells, Rimiducid (AP1903), Lymphodepleting Chemotherapy
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 22, 2026, 3:48 AM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
GDX012 Suspension for IV Infusion
Biological
Lead sponsor
GammaDelta Therapeutics Limited
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced May 22, 2026, 3:48 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
Interventions
Ibrutinib, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced May 22, 2026, 3:48 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Nsclc, NSCLC Stage IV, Minimal Residual Disease, Non Small Cell Lung Cancer Metastatic
Interventions
Local ablative therapy, Blood collection to assess for ctDNA
Procedure · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
9
States / cities
Hartford, Connecticut • Miami, Florida • Basking Ridge, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced May 22, 2026, 3:48 AM EDT
Terminated No phase listed Observational
View directory record Official record
Conditions
Leukemia, Myeloid, Acute, Minimal Residual Disease
Interventions
Not listed
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 4, 2024 · Synced May 22, 2026, 3:48 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
Ofatumumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced May 22, 2026, 3:48 AM EDT
Terminated Phase 4 Interventional Results available
View directory record Official record
Conditions
B-precursor Acute Lymphoblastic Leukemia
Interventions
Blinatumomab, Current Wearable Heatlth Monitoring System (CWHMS)
Drug · Device
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
12
States / cities
Duarte, California • Los Angeles, California • Orange, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 17, 2025 · Synced May 22, 2026, 3:48 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
B-Cell Acute Lymphoblastic Leukemia
Interventions
CTL019
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Year to 25 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced May 22, 2026, 3:48 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2030
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced May 22, 2026, 3:48 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Daratumumab, Lenalidomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced May 22, 2026, 3:48 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck, Squamous Cell Carcinoma Head and Neck Cancer (HNSCC), Squamous Cell Carcinoma of Skin, Cutaneous Squamous Cell Carcinoma (CSCC)
Interventions
Blood Specimen Collection, Tumor Tissue Collection, Medical Record Review
Procedure · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced May 22, 2026, 3:48 AM EDT
Suspended Phase 1 Interventional
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission, Hematopoietic Cell Transplantation Recipient, Minimal Residual Disease, Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia
Interventions
Fludarabine, Laboratory Biomarker Analysis, Melphalan, Total Marrow Irradiation
Drug · Other · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
12 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced May 22, 2026, 3:48 AM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Lymphoma, Lymphoma, B-Cell, Diffuse Large B Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High-grade B-cell Lymphoma
Interventions
Phased Variant Enrichment and Detection Sequencing (PhasED-seq), Standard of Care Treatment, De-escalated Treatment
Device · Other
Lead sponsor
Hua-Jay J Cherng, MD
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced May 22, 2026, 3:48 AM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, CD19 Positive, Minimal Residual Disease, Philadelphia Chromosome Positive, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
Interventions
Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Questionnaire Administration
Biological · Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
1 Year to 30 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2035
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 28, 2025 · Synced May 22, 2026, 3:48 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma (DLBCL)
Interventions
Mosunetuzumab, ClonoSEQ
Drug · Device
Lead sponsor
Danielle Wallace
Other
Eligibility
70 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced May 22, 2026, 3:48 AM EDT